123 related articles for article (PubMed ID: 38731416)
21. Probes for narcotic receptor mediated phenomena. Part 42: synthesis and in vitro pharmacological characterization of the N-methyl and N-phenethyl analogues of the racemic ortho-c and para-c oxide-bridged phenylmorphans.
Kim JH; Deschamps JR; Rothman RB; Dersch CM; Folk JE; Cheng K; Jacobson AE; Rice KC
Bioorg Med Chem; 2011 Jun; 19(11):3434-43. PubMed ID: 21570305
[TBL] [Abstract][Full Text] [Related]
22. Role of efficacy as a determinant of locomotor activation by mu-opioid receptor (MOR) ligands in female and male mice. II. Effects of novel MOR-selective phenylmorphans with high-to-low MOR efficacy.
Santos EJ; Nassehi N; Bow EW; Chambers DR; Gutman ES; Jacobson AE; Lutz JA; Marsh SA; Rice KC; Sulima A; Selley DE; Negus SS
Pharmacol Res Perspect; 2023 Aug; 11(4):e01111. PubMed ID: 37381112
[TBL] [Abstract][Full Text] [Related]
23. Probes for narcotic receptor mediated phenomena. Part 28: new opioid antagonists from enantiomeric analogues of 5-(3-hydroxyphenyl)-N-phenylethylmorphan.
Hashimoto A; Jacobson AE; Rothman RB; Dersch CM; George C; Flippen-Anderson JL; Rice KC
Bioorg Med Chem; 2002 Oct; 10(10):3319-29. PubMed ID: 12150879
[TBL] [Abstract][Full Text] [Related]
24. SAR Matrices Enable Discovery of Mixed Efficacy μ-Opioid Receptor Agonist Peptidomimetics with Simplified Structures through an Aromatic-Amine Pharmacophore.
Henry S; Anand JP; Brinkel AC; McMillan DM; Twarozynski JJ; Loo CE; Traynor JR; Mosberg HI
ACS Chem Neurosci; 2021 Jan; 12(1):216-233. PubMed ID: 33346631
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
26. Affinity, potency, efficacy, selectivity, and molecular modeling of substituted fentanyls at opioid receptors.
Eshleman AJ; Nagarajan S; Wolfrum KM; Reed JF; Nilsen A; Torralva R; Janowsky A
Biochem Pharmacol; 2020 Dec; 182():114293. PubMed ID: 33091380
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological properties of TRK-820 on cloned mu-, delta- and kappa-opioid receptors and nociceptin receptor.
Seki T; Awamura S; Kimura C; Ide S; Sakano K; Minami M; Nagase H; Satoh M
Eur J Pharmacol; 1999 Jul; 376(1-2):159-67. PubMed ID: 10440101
[TBL] [Abstract][Full Text] [Related]
28. Morphinan derivatives with an oxabicyclo[3.2.1]octane structure as dual agonists toward δ and κ opioid receptors.
Uenohara Y; Tsumura S; Hirayama S; Higashi E; Watanabe Y; Gouda H; Nagase H; Fujii H
Bioorg Med Chem; 2022 Jan; 53():116552. PubMed ID: 34894610
[TBL] [Abstract][Full Text] [Related]
29. A critical structural determinant of opioid receptor interaction with phenolic 5-phenylmorphans.
Kim IJ; Dersch CM; Rothman RB; Jacobson AE; Rice KC
Bioorg Med Chem; 2004 Aug; 12(16):4543-50. PubMed ID: 15265502
[TBL] [Abstract][Full Text] [Related]
30. Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.
Wang Y; Tang K; Inan S; Siebert D; Holzgrabe U; Lee DY; Huang P; Li JG; Cowan A; Liu-Chen LY
J Pharmacol Exp Ther; 2005 Jan; 312(1):220-30. PubMed ID: 15383632
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and Structure-Activity Relationships of (-)-
Pasquinucci L; Parenti C; Amata E; Georgoussi Z; Pallaki P; Camarda V; Calò G; Arena E; Montenegro L; Turnaturi R
Pharmaceuticals (Basel); 2018 May; 11(2):. PubMed ID: 29734749
[TBL] [Abstract][Full Text] [Related]
32. Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.
Harland AA; Yeomans L; Griggs NW; Anand JP; Pogozheva ID; Jutkiewicz EM; Traynor JR; Mosberg HI
J Med Chem; 2015 Nov; 58(22):8952-69. PubMed ID: 26524472
[TBL] [Abstract][Full Text] [Related]
33. Synthesis, Pharmacology, and Molecular Docking Studies on 6-Desoxo-N-methylmorphinans as Potent μ-Opioid Receptor Agonists.
Dumitrascuta M; Ben Haddou T; Guerrieri E; Noha SM; Schläfer L; Schmidhammer H; Spetea M
J Med Chem; 2017 Nov; 60(22):9407-9412. PubMed ID: 29053268
[TBL] [Abstract][Full Text] [Related]
34. Opioid peptide receptor studies. 14. Stereochemistry determines agonist efficacy and intrinsic efficacy in the [(35)S]GTP-gamma-S functional binding assay.
Xu H; Hashimoto A; Rice KC; Jacobson AE; Thomas JB; Carroll FI; Lai J; Rothman RB
Synapse; 2001 Jan; 39(1):64-9. PubMed ID: 11071711
[TBL] [Abstract][Full Text] [Related]
35. Mechanistic Characterization of the Pharmacological Profile of HS-731, a Peripherally Acting Opioid Analgesic, at the µ-, δ-, κ-Opioid and Nociceptin Receptors.
Puls K; Schmidhammer H; Wolber G; Spetea M
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164182
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for
Obeng S; Wilkerson JL; León F; Reeves ME; Restrepo LF; Gamez-Jimenez LR; Patel A; Pennington AE; Taylor VA; Ho NP; Braun T; Fortner JD; Crowley ML; Williamson MR; Pallares VLC; Mottinelli M; Lopera-Londoño C; McCurdy CR; McMahon LR; Hiranita T
J Pharmacol Exp Ther; 2021 Mar; 376(3):410-427. PubMed ID: 33384303
[TBL] [Abstract][Full Text] [Related]
37. Pharmacologic Characterization of Substituted Nitazenes at
Kozell LB; Eshleman AJ; Wolfrum KM; Swanson TL; Bloom SH; Benware S; Schmachtenberg JL; Schutzer KA; Schutzer WE; Janowsky A; Abbas AI
J Pharmacol Exp Ther; 2024 Apr; 389(2):219-228. PubMed ID: 38453524
[TBL] [Abstract][Full Text] [Related]
38. Identification of a novel "almost neutral" micro-opioid receptor antagonist in CHO cells expressing the cloned human mu-opioid receptor.
Sally EJ; Xu H; Dersch CM; Hsin LW; Chang LT; Prisinzano TE; Simpson DS; Giuvelis D; Rice KC; Jacobson AE; Cheng K; Bilsky EJ; Rothman RB
Synapse; 2010 Apr; 64(4):280-8. PubMed ID: 19953652
[TBL] [Abstract][Full Text] [Related]
39. Novel ligands for the opioid receptors: synthesis and structure-activity relationships among 5'-aryl and 5'-heteroaryl 17-cyclopropylmethyl-4,5 alpha-epoxypyrido[2',3':6,7]morphinans.
Ananthan S; Khare NK; Saini SK; Davis P; Dersch CM; Porreca F; Rothman RB
Bioorg Med Chem; 2003 Sep; 11(18):4143-54. PubMed ID: 12927876
[TBL] [Abstract][Full Text] [Related]
40. Effect of N-alkyl and N-alkenyl substituents in noroxymorphindole, 17-substituted-6,7-dehydro-4,5alpha-epoxy-3,14-dihydroxy-6,7:2',3'-indolomorphinans, on opioid receptor affinity, selectivity, and efficacy.
McLamore S; Ullrich T; Rothman RB; Xu H; Dersch C; Coop A; Davis P; Porreca F; Jacobson AE; Rice KC
J Med Chem; 2001 Apr; 44(9):1471-4. PubMed ID: 11311071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
